New Launch15 Oct 2025, 02:35 pm
AstraZeneca Pharma India to Launch Lokelma for Hyperkalaemia Treatment in November 2025
AI Summary
AstraZeneca Pharma India Limited has announced the launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in India. The drug, which received Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India, is indicated for the treatment of hyperkalaemia in adult patients. This announcement comes after the company's earlier communication dated March 6, 2025, where they first intimated about the receipt of the permission.
Key Highlights
- AstraZeneca Pharma India Limited to launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025
- Lokelma is indicated for the treatment of hyperkalaemia in adult patients
- The drug received Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India
- This announcement is a follow-up to the company's earlier communication dated March 6, 2025